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Background and objectives: Angiotensin-converting enzyme inhibitors (ACEI) and 
angiotensin receptor blockers (ARB) are increasingly used in a variety of settings including heart 
failure, renal failure, arterial hypertension, and diabetic nephropathy. The objective of this study 
was to investigate the prevalence of hyperkalemia with ACEI and ARB use, in a population of 
the United States veterans.
Design, settings, material, and measurements: Retrospective observational cohort study 
of 1163 patients on ACEIs and 1168 patients on ARBs in a single Veterans Affairs Medical 
Center. Electronic medical records were reviewed over a 12-month period with data collected 
on various demographic, laboratory, comorbidity, and medication related variables.
Results: Hyperkalemia (5 mEq/L) was observed in 20.4% of patients on ACEIs and 31.0% 
on ARBs. Severe hyperkalemia (6 mEq/L or higher), was observed in 0.8% of ACEI and 2.8% 
of ARB users. In univariate logistic regression analyses, diabetes mellitus; serum glucose, total 
carbon dioxide content, creatinine, and estimated glomerular filtration rate (GFR) were signifi-
cantly associated with hyperkalemia. ARB use, when compared to ACEI, was associated with a 
42% increase in odds of hyperkalemia (odds ratio [OR] = 1.42; p = 0.001) in a model including 
adjustment for GFR and a 56% increase in odds of hyperkalemia (OR = 1.56; p  0.001) in a 
model including adjustment for serum creatinine.
Conclusions: Hyperkalemia, associated with the use of ACEIs and ARBs, is usually mild and 
severe hyperkalemia is rare. Hyperkalemia is more common with ARBs than ACEIs. ARB use, 
when compared to ACEI use, may significantly and independently be associated with increased 
odds of hyperkalemia.
Keywords: hyperkalemia, angiotensin-converting enzyme inhibitors, angiotensin receptor 
blockers
Introduction
Over the past four decades, many advances have taken place in the management of 
heart failure, diabetic nephropathy, arterial hypertension, and chronic kidney disease. 
These advances have included use of angiotensin-converting enzyme inhibitors 
(ACEIs),1 angiotensin receptor blockers (ARBs), and more recently, renin blockers. 
Use of ACEIs2 and ARBs3 has contributed to better outcomes in heart failure with less 
need for hospitalization, improved functional class, and decreased mortality. Similarly, 
ACEIs and ARBs have shown efficacy in decreasing proteinuria, and slowing the 
progression of diabetic nephropathy. Their use, however, is sometimes complicated Therapeutics and Clinical Risk Management 2009:5 548
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by hyperkalemia that may necessitate their discontinuation. 
It is also estimated that as many as 5% to 10% of patients 
with congestive heart failure (CHF) may not tolerate ACEIs 
due to hypotension or azotemia, but do better with ARBs.4 
Some studies,5 have shown a reduced prevalence of hyper-
kalemia with ARBs possibly due to less suppression of 
aldosterone secretion,6 but others have not confirmed this 
effect.7 If confirmed, substituting ARBs for ACEIs becomes 
a plausible alternative in patients who desperately need the 
beneficial effects of renin–angiotensin–aldosterone system 
blockade. Therefore, we decided to examine and compare 
the prevalence of hyperkalemia in a large veteran population 
receiving ACEIs and ARBs to explore factors that increase 
the risk of hyperkalemia.
Methods
We investigated the prevalence, magnitude, and independence 
of the association of ACEI and ARB use with hyperkalemia 
in a population of the United States veterans after receiving 
approval from our local institutional review board. The 
pharmacy service provided a list of several thousand patients 
receiving these medications. Through randomized selection, 
1,163 patients receiving ACEIs and 1,168 patients receiving 
ARBs were included in the study. Using a computerized 
patient record system (CPRS), serum potassium over a 
12-month period was reviewed, the highest value identified, 
and concurrent laboratory values recorded. Information was 
collected on various demographic, comorbid, and laboratory 
variables including age, body mass index (BMI), presence or 
absence of ICD-9-CM classified heart failure (CHF), diabetes 
mellitus (DM), arterial hypertension (HTN), chronic kidney 
disease (CKD), serum sodium, potassium, chloride, total 
carbon dioxide content (CO2), blood urea nitrogen (BUN), 
serum creatinine (Cr), and GFR estimated by a four-variable 
modification of diet in renal disease formula (MDRD). 
Information was also collected on medication usage: 
ACEI type and dose, ARB type and dose, and concomitant 
nonsteroidal anti-inflammatory drug (NSAID), diuretic, and 
potassium supplement use. Patients who were on ACEIs or 
ARBs with missing clinical and laboratory variables were 
excluded. This accounted for 11% of screened patients. 
Hyperkalemia was defined as serum potassium level higher 
than 5 mEq/L that was observed on at least one occasion dur-
ing the 12-month period preceding the analysis. Comparison 
of groups was done by Student’s t-test for normally distributed 
continuous variables and Pearson’s chi-squared test for 
categorical variables. A p-value less than 0.05 was consid-
ered significant. Univariate logistic regression was used to 
determine the association of each variable of interest with 
hyperkalemia. For each variable significantly associated with 
hyperkalemia, bivariate logistic regression was performed to 
determine which of these factors resulted in a greater than 10% 
change in the odds of hyperkalemia for ARB use when com-
pared to ACEI use. To achieve optimal model stability, these 
factors were then included in a multivariate logistic regression 
analysis to determine the adjusted odds of hyperkalemia for 
ARB use in reference to ACEI use.
Results
Comparison of ACei and ARB users
Table 1 details demographics, associated medical conditions, 
simultaneous medication use, and CKD stage of the two 
groups. There were no significant differences between 
the two groups with regard to age, gender, BMI, diabetes 
mellitus, or hypertension; but CHF was more common in 
ARB users (17.1 vs 9.5%). Serum creatinine (1.47 ± 1.03 vs 
1.25 ± 0.64 mg/dL; p  0.001) was significantly higher and 
Table 1 Patient demographics, associated conditions, and medi-
cation use
ACEI ARB P Value
number 1163 1168
Mean age, years 67.5 ± 10.9 67.2 ± 10.7 0.439
BMi, kg/m2 30.7 ± 6.9 31.3 ± 7.3 0.025
Diabetes mellitus (%) 51.5 52.1 0.649
hypertension (%) 91.7 92.9 0.326
heart failure (%) 9.5 17.1 0.001
Creatinine mg/dL 1.25 ± 0.64 1.47 ± 1.03 0.001
egFR ml/min/1.73 m2 69.0 ± 21.4 60.9 ± 20.7 0.001
glucose mg/dL 130.9 ± 57.8 141.0 ± 76.4 0.809
Total CO2 meq/L 27.4 ± 2.9 27.7 ± 3.9 0.001
Loop diuretics (%) 14.7 24.4 0.001
Thiazides (%) 26.7 28.4 0.379
Potassium-sparing 
diuretics (%)
6.1 11.1 0.001
Potassium chloride (%) 6 13.1 0.001
nSAiDS (%) 17 17.5 0.784
CKD stage 1 (%) 16.2 8.2 0.001
CKD stage 2 (%) 51.4 46.0 0.009
CKD stage 3 (%) 30.1 39.9 0.001
CKD stage 4 (%) 1.7 4.6 0.001
CKD stage 5 (%) 0.6 1.3 0.089
Abbreviations: ACei, angiotensin-converting enzyme inhibitors; ARB, angiotensin 
receptor blockers; BMi, body mass index; CKD, chronic kidney disease; gFR, glomerular 
filtration rate; NSAIDs, nonsteroidal anti-inflammatory drugs.Therapeutics and Clinical Risk Management 2009:5 549
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GFR was significantly lower in ARB users (60.0 ± 20.7 
vs 69.0 ± 21.4 mL/min/1.73 m2 body surface area [BSA]; 
p = 0.001). Use of loop diuretics (24.4% vs 14.7%, p  0.001), 
potassium-sparing diuretics (11.1% vs 6.1%; p  0.001), 
and potassium supplements (13.1% vs 6.0%; p  0.001) was 
significantly higher in ARB compared to ACEI users. When 
grouped according to CKD stage, the distribution of GFR 
was significant for more advanced kidney disease among 
ARB users: 39.9% vs 30.1% for stage III, 4.6% vs 1.7% for 
stage IV, and 1.3% vs 0.6% for stage V.
Of the 1,136 patients on ACEI, 831 (71.0%) were on 
lisinopril, 225 (19.3%) on benazepril, 84 (7.2%) on fosinopril, 
12 (1.0%) on enalapril, and 11 (0.8%) on captopril. Among 
ARB users, 1126 (96.4%) were on irbesartan and 42 (3.5%) 
on losartan (ARB use was restricted by hospital formulary). 
Mean daily dosage of these medications were as follows: 
lisinopril 29.4 ± 13.8 mg, benazepril 31.2 ± 12 mg, fosinopril 
34 ± 12.1 mg, enalapril 9.5 ± 3.9 mg, captopril 68.7 ± 47.8 mg, 
irbesartan 202.3 ± 87.4 mg, and losartan 66.6 ± 33.3 mg.
Comparison of hyperkalemic ACei  
and ARB Users
Hyperkalemia, serum potassium 5.0 mEq/L on at least 
one occasion and over a one-year period, was observed in 
238 (20.4%) of ACEI users vs 361 (31.0%) of ARB users. 
Serum potassium, when stratified by the level of hyperkalemia 
from 5.0 to 5.50, 5.6 to 5.9, and 6.0 mEq/L or higher was 
seen in 16.6%, 4.9%, and 0.8% of ACEI users vs 22.3%, 
5.8%, 2.8% of ARB users, respectively. Among diabetics, 
143 (24%) on ACEI therapy and 229 (37.7%) on ARB therapy 
were hyperkalemic, with mean GFR of 68.7 ± 22.9 in ACEI 
vs 58.7 ± 21.3 ml/min in ARB users. Hyperkalemia was 
seen in 30.6% of patients on irbesartan or losartan, 27.2% on 
captopril, 21.7% on fosinopril, 21.5% on lisinopril, and 16.5% 
on benazepril. One hundred seventy five patients were on 
combined ACEI and ARB. Of these, 48 (27.4%) had a serum 
potassium 5.0, 14 (8.0%) had a serum potassium 5.5, and 
4 (2.2%) had a serum potassium of 6 mEq/L or higher. Table 2 
shows comparison of hyperkalemic patients on ACEIs and 
ARBs. Among hyperkalemic patients, ARB users had signifi-
cantly higher mean BUN and serum creatinine, but a lower 
GFR. Concomitant use of potassium sparing diuretics (17.5% 
vs 8.0%) and nonpotassium-sparing diuretics (48.0% vs 38.0%) 
was significantly higher among hyperkalemic ARB users.
Logistic regression analysis
Of the demographic-, comorbidity-, laboratory-, and 
medication-related variables studied, we identified four 
factors significantly associated with hyperkalemia, which 
in bivariate logistic regression analysis were found 
to result in greater than 10% change in the odds ratio 
(OR) of hyperkalemia for ARBs in reference to ACEIs. 
Specifically, these included serum glucose, BUN, Cr, and 
GFR. Notably, none of the other variables we studied, 
including diabetes, CHF, CO2, nonpotassium-sparing and 
potassium-sparing diuretic use, NSAID use, or potassium 
supplement use significantly affected the odds of hyperkalemia 
for ARBs in reference to ACEIs. Blood glucose, BUN, and 
Cr were positively correlated, while GFR was negatively 
correlated with hyperkalemia (p  0.001). Due to collinearity 
between three of these variables, (BUN, Cr, and GFR), we 
developed two separate multiple logistic regression models 
to determine the adjusted odds of hyperkalemia for ARBs 
in reference to ACEIs. In the first model, we included the 
GFR, and in the second model, we included the serum Cr. 
In univariate logistic regression analysis, ARB use was 
associated with a 73% increase in crude OR for hyperkalemia 
(OR = 1.739; p  0.001). After adjusting for blood glucose 
and GFR, there was still an increased risk of hyperkalemia 
with ARBs (OR = 1.43; p = 0.001). Even after adjusting for 
blood glucose and serum Cr, risk of hyperkalemia with ARBs 
(OR = 1.56; p  0.001) compared to ACEIs persisted.
Discussion
ACEIs, along with beta blockers,8 spironolactone,9 and 
eplerenone10 have proven themselves to be of great benefit in 
the management of patients with left ventricular dysfunction. 
Table 2 Comparison of hyperkalemic patients receiving ACei 
or ARBs
ACEI ARB p value
238 361
Age, years 68.6 ± 10.8 68.2 ± 10.5 nS
BMi, Kg/m2 BSA 30.3 ± 6.3 30.4 ± 5.8 nS
glucose mg/dL 142.3 ± 79.4 148.7 ± 81.0 nS
BUn mg/dL 23.8 ± 14.8 30.2 ± 16.9 0.001
Creatinine mg/dL 1.44 ± 0.79 1.82 ± 1.35 0.001
CO2 content 26.89 ± 3.42 26.73 ± 3.58 nS
DM % 60.0 63.0 nS
Potassium-sparing diuretic % 8.0 17.5 0.001
nonpotassium-sparing 
diuretic %
38.0 48.0 0.016
egFR ml/min/1.73 m2 BSA 60.88 ± 21.2 51.5 ± 21.2 0.001
Abbreviations: ACei, angiotensin-converting enzyme inhibitors; ARB, angiotensin 
receptor blockers; BMi, body mass index; BSA, body surface area; BUn, blood urea 
nitrogen; DM, diabetes mellitus; GFR, glomerular filtration rate; NS, Not significant.Therapeutics and Clinical Risk Management 2009:5 550
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Their use has become part of accepted regimens of treatment 
and a yardstick of quality of care provided to these patients.11 
ACEI s and ARBs have also been found to be effective 
in preserving renal function12 in patients with diabetes 
mellitus and also in nondiabetic conditions like polycystic 
kidney disease,13,14 idiopathic nephrotic syndrome and Ig A 
nephropathy.15,16 Combined use of ACEI and ARB has been 
advocated by some studies17–19 but not all to be more effective 
in preserving renal function.20
Every patient with heart failure and diabetes mellitus, 
even those that are not hypertensive are expected to receive 
these medications unless there is an untoward reaction to 
their use, like, angioedema, progressive renal failure, or 
hyperkalemia.
Hyperkalemia, because of its serious consequences, 
like cardiac arrhythmia and death,21,22 frequently compels 
physicians to discontinue these medications, especially in 
those with kidney disease. Opinions vary as to what level 
of hyperkalemia requires action. Some would advocate 
a level of 8 mEq/L or higher23 as grounds for hospitalization, 
while others feel very uneasy leaving a patient with a serum 
potassium level higher than 5 mEq/L on these agents. 
In our study we found that although hyperkalemia (serum 
potassium 5 mEq/L) can be seen in as many as 30% of 
patients, severe hyperkalemia (6 mEq/L), is observed 
only in about 1% to 3% of patients. Higher prevalence of 
hyperkalemia with ARBs (31% vs 20.4%) in our study 
may be due to higher prevalence of CHF in this group, 
higher use of potassium-sparing diuretics and potassium 
replacement therapy, and the switching of hyperkalemic 
patients from ACEI to ARBs due to the widely held belief 
among physicians that ARBs cause less hyperkalemia than 
ACEIs. However, even after accounting for all the above 
mentioned factors, and although the association weakened, 
ARB use was still associated with a significant increase in 
odds risk for hyperkalemia.
In our study hyperkalemia was more common, compared 
to controlled studies, where ARBs were used primarily 
for the treatment of heart failure or nephropathy in patient 
populations with normal or near normal kidney function 
and where hyperkalemia was not the primary study focus 
(Table 3). Bakris and colleagues6 and Preston and colleagues7 
compared the effect of ACEIs and ARBs on serum potassium 
concentration. In the former study, there were 35 patients with 
a mean GFR of 65 ± 5 mL/min and there was less increase in 
serum potassium with valsartan than with lisinopril (0.12 vs 
0.28 mEq/L). In the latter study, 24 diabetic patients who 
had normal renal function (Cr clearance 109 mL/min), 
were treated with candesartan and lisinopril. No difference 
in fractional excretion of potassium or serum potassium 
concentration was observed. However, in posthoc analyses 
of RENAAL study, Winklemayer and colleagues24 and Appel 
and colleagues25 reported hyperkalemia (value not reported) 
in 24.3% of losartan treated patients vs 12.3% of controls and 
discontinuation of treatment in 1.3% of patients because of 
hyperkalemia. The prevalence rate of hyperkalemia in this 
randomized controlled study is very similar to the results 
of our study.
Some of the hyperkalemia observed in our study may be 
artifactual, related to the technique of blood drawing26and 
some due to the fact that most of our patients had moder-
ate to advanced renal and heart failure where there is more 
likelihood of renal dysfunction and hyperkalemia.27,28 
However, as previously noted, the observed associations 
between hyperkalemia and ARB use in reference to ACEI 
use persisted even after adjustment for renal function.
Our study has some limitations. First is the fact that it 
was retrospective and observational in nature and it can 
not provide any information on the time frame of develop-
ment of hyperkalemia after the start of ACEIs or ARBs. 
Second, it was limited to a veteran population at a single 
center and may not be generalizable to other populations. 
Third, there may have been a tendency among practitioners 
to preferentially prescribe ARBs over ACEIs to patients 
with a higher disease severity, introducing the possibility 
for confounding by indication, a type of selection bias. 
Lastly, causal inference regarding the effect of ARB use in 
reference to ACEIs use cannot be drawn from this study due 
to its observational nature. Nevertheless, the validity of our 
study findings are supported by the detection of other well 
established associations between other study variables and 
hyperkalemia, which occurred in the direction and magnitude 
expected based on previous reports in the literature.
In conclusion, use of ACEIs and ARBs is associated with 
a high prevalence of hyperkalemia, but more so with ARBs. 
Most patients can and should benefit from the beneficial 
effects of these agents, but caution should be exercised 
especially in those with advanced kidney disease, heart 
failure, on renal replacement therapy, on potassium sparing 
diuretics and KCl replacement therapy.29 We agree with 
Palmer30 that ACEIs or ARBs should be discontinued 
once serum potassium exceeds 5.5 mEq/L, unless it can 
be controlled with diet, diuretics or sodium polystyrene 
sulfonate. As it has been recommended by others, we would 
advise checking of serum potassium level in one week after 
any change in ACEI or ARB dosing.Therapeutics and Clinical Risk Management 2009:5 551
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